The present invention relates to a method for converting at least one oligo- and/or polysaccharide into fructose comprising the steps of: a) adding to a composition comprising water, phosphate and at least one oligo- and/or polysaccharide at least four enzymes, and b) subsequently enzymatically converting the at least one oligo- and/or polysaccharide to fructose in the presence of the at least four enzymes, wherein in step a) at least one additional saccharide is added, whereby the at least one additional saccharide is selected from the group consisting of saccharides comprising 20 or less monosaccharide residues and/or combinations thereof; wherein in step a) the at least four enzymes, preferably at least five enzymes, are selected from the group consisting of transferases, phosphorylases, mutases, isomerases, hydrolases, phosphatases and combinations thereof; and wherein at least one enzyme in step a) is a phosphatase.

Described is a method for the production of fructose-6-phosphate (F6P) from dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P) comprising the steps of: (a) enzymatically converting dihydroxyacetone phosphate (DHAP) into dihydroxyacetone (DHA); and (b) enzymatically converting the thus produced dihydroxyacetone (DHA) and glyceraldehyde-3-phosphate (G3P) into fructose-6-phosphate (F6P); or
comprising the steps of: (a′) enzymatically converting glyceraldehyde-3-phosphate (G3P) into glyceraldehyde; and (b′) enzymatically converting the thus produced glyceraldehyde together with dihydroxyacetone phosphate (DHAP) into fructose-1-phosphate (F1P); and (c′) enzymatically converting the thus produced fructose-1-phosphate (F1P) into fructose-6-phosphate (F6P).

The present invention relates to an inhibitor of sphingolipids for use in the treatment or prevention of an aging related-disease and/or aging.

Described is a method for the production of fructose-6-phosphate (F6P) from dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (G3P) comprising the steps of: (a) enzymatically converting dihydroxyacetone phosphate (DHAP) into dihydroxyacetone (DHA); and (b) enzymatically converting the thus produced dihydroxyacetone (DHA) and glyceraldehyde-3-phosphate (G3P) into fructose-6-phosphate (F6P); or
comprising the steps of: (a′) enzymatically converting glyceraldehyde-3-phosphate (G3P) into glyceraldehyde; and (b′) enzymatically converting the thus produced glyceraldehyde together with dihydroxyacetone phosphate (DHAP) into fructose-1-phosphate (F1P); and (c′) enzymatically converting the thus produced fructose-1-phosphate (F1P) into fructose-6-phosphate (F6P).

The present disclosure relates to a diagnostic assay to detect classic inborn galactosemia. The assay comprises detecting defective galactose metabolism using a substrate-specific recombinant phosphatase derived from Salmonella.